Characteristic | N (%) |
---|---|
Age (Years) [Mean (SD), range] | 45.97 (9.00), 18–65 |
Gender | Â |
 Female | 268 (95.4%) |
 Male | 13 (4.6%) |
Marital status | Â |
 Single | 55 (19.6%) |
 Married | 148 (52.7%) |
 Cohabitation | 34 (12.1%) |
 Divorced or separated | 43 (15.3%) |
 Widowed | 1 (0.4%) |
Children (Yes) | 211 (75.1%) |
Education | Â |
 Less than 4 years of education | 1 (0.4%) |
 1st Cycle (4th year complete) | 5 (1.8%) |
 2nd Cycle (6th year complete) | 4 (1.4%) |
 3rd Cycle (9th year complete) | 13 (4.6%) |
 Secondary Education (12th year complete) | 87 (30.9%) |
 Higher Education—Bachelor’s degree | 117 (41.7%) |
 Higher Education—Master’s degree | 48 (17.1%) |
 Higher Education—Doctoral degree | 6 (2.1%) |
Education (Years) [Mean (SD), range] | 15.56 (3.87), 4–29 |
Occupation | Â |
 Working (part- and full-time) | 185 (66.1%) |
 Medical leave | 56 (20.1%) |
 Unemployed | 20 (7.2%) |
 Student | 6 (2.2%) |
 Retired | 14 (5.0%) |
Monthly income (euros) | Â |
 < 500€ | 28 (10%) |
 500€–999€ | 104 (37.0%) |
 1000€–1499€ | 77 (27.4%) |
 1500€–1999€ | 45 (16.0%) |
 > 2000€ | 27 (9.6%) |
Cancer type | Â |
 Bladder | 1 (0.4%) |
 Lung | 8 (2.8%) |
 Uterus | 3 (1.1%) |
 Leukemia | 5 (1.7%) |
 Hodgkin Lymphoma | 17 (6.0%) |
 Non-Hodgkin Lymphoma | 10 (3.6%) |
 Melanoma | 3 (1.1%) |
 Multiple Myeloma | 3 (1.1%) |
 Cervical | 6 (2.1%) |
 Colorectal | 17 (6.0%) |
 Stomach | 2 (0.7%) |
 Breast | 176 (62.7%) |
 Ovarian | 11 (3.9%) |
 Skin non-melanoma | 3 (1.1%) |
 Thyroid | 6 (2.3%) |
 Other (e.g., nasopharynx, liver, sarcoma) | 10 (3.9%) |
Year of cancer diagnosis | Â |
 ≤ 2000 | 3 (1.1%) |
 2001–2005 | 3 (1.1%) |
 2006–2010 | 24 (9.5%) |
 2011–2015 | 80 (31.9%) |
 2016–2021 | 171 (68.3%) |
Previous treatments | Â |
 None | 7 (2.5%) |
 Surgery | 233 (82.9%) |
 Radiation therapy | 168 (59.8%) |
 Chemotherapy | 227 (80.8%) |
 Hormone therapy | 138 (49.1%) |
 Immunotherapy | 39 (13.9%) |
 Other | 41 (14.6%) |
Ongoing treatments | Â |
 None | 161 (57.3%) |
 Surgery | 0 (0.0%) |
 Radiation therapy | 7 (2.5%) |
 Chemotherapy | 14 (5.0%) |
 Hormone therapy | 84 (29.9%) |
 Immunotherapy | 13 (4.6%) |
 Other | 19 (6.8%) |
Use of mental health services (Yes) | 72 (25.6%) |